Compugen (CGEN) - Cash Flow Conversion Efficiency

Latest as of December 2022: 0.056x

Based on the latest financial reports, Compugen (CGEN) has a cash flow conversion efficiency ratio of 0.056x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA4.33 Million ≈ $11.60K USD) by net assets (ILA77.68 Million ≈ $208.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Compugen (CGEN) market capitalisation for the company's overall valuation and market capitalisation.

Compugen - Cash Flow Conversion Efficiency Trend (1999–2025)

This chart illustrates how Compugen's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Compugen Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Compugen ranked by their cash flow conversion efficiency. Explore CGEN cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Berjaya Assets Bhd
KLSE:3239
0.032x
Melar Acquisition Corp. I Unit
NASDAQ:MACIU
-0.001x
Savior Lifetec
TWO:4167
-0.026x
Inversora Juramento SA
BA:INVJ
-0.033x
Saraswanti Anugerah Makmur Pt
JK:SAMF
0.243x
TIL Limited
NSE:TIL
-0.256x
HIL Limited
NSE:HIL
0.049x
ZHOU HEI YA HLDG -000001
F:ZHY
N/A

Annual Cash Flow Conversion Efficiency for Compugen (1999–2025)

The table below shows the annual cash flow conversion efficiency of Compugen from 1999 to 2025. View Compugen (CGEN) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ILA102.73 Million
≈ $275.42K
ILA31.63 Million
≈ $84.81K
0.308x -65.91%
2024-12-31 ILA54.91 Million
≈ $147.22K
ILA49.60 Million
≈ $132.99K
0.903x +265.02%
2023-12-31 ILA65.56 Million
≈ $175.76K
ILA-35.89 Million
≈ $-96.21K
-0.547x -24.65%
2022-12-31 ILA77.68 Million
≈ $208.26K
ILA-34.11 Million
≈ $-91.46K
-0.439x -105.95%
2021-12-31 ILA106.69 Million
≈ $286.04K
ILA-22.75 Million
≈ $-60.99K
-0.213x +9.81%
2020-12-31 ILA119.78 Million
≈ $321.13K
ILA-28.32 Million
≈ $-75.92K
-0.236x +67.51%
2019-12-31 ILA38.32 Million
≈ $102.74K
ILA-27.89 Million
≈ $-74.77K
-0.728x -103.92%
2018-12-31 ILA37.24 Million
≈ $99.85K
ILA-13.29 Million
≈ $-35.63K
-0.357x +65.90%
2017-12-31 ILA29.30 Million
≈ $78.54K
ILA-30.66 Million
≈ $-82.19K
-1.046x -235.38%
2016-12-31 ILA63.52 Million
≈ $170.29K
ILA-19.82 Million
≈ $-53.13K
-0.312x -9.54%
2015-12-31 ILA89.90 Million
≈ $241.01K
ILA-25.61 Million
≈ $-68.65K
-0.285x -170.78%
2014-12-31 ILA105.97 Million
≈ $284.12K
ILA-11.15 Million
≈ $-29.89K
-0.105x +47.90%
2013-12-31 ILA31.89 Million
≈ $85.49K
ILA-6.44 Million
≈ $-17.26K
-0.202x +67.10%
2012-12-31 ILA17.67 Million
≈ $47.38K
ILA-10.85 Million
≈ $-29.08K
-0.614x -29.93%
2011-12-31 ILA19.58 Million
≈ $52.50K
ILA-9.25 Million
≈ $-24.80K
-0.472x -212.23%
2010-12-31 ILA28.29 Million
≈ $75.83K
ILA-4.28 Million
≈ $-11.47K
-0.151x +44.39%
2009-12-31 ILA27.40 Million
≈ $73.45K
ILA-7.45 Million
≈ $-19.98K
-0.272x +72.82%
2008-12-31 ILA10.00 Million
≈ $26.82K
ILA-10.01 Million
≈ $-26.84K
-1.001x -105.79%
2007-12-31 ILA17.29 Million
≈ $46.34K
ILA-8.41 Million
≈ $-22.54K
-0.486x -26.03%
2006-12-31 ILA25.74 Million
≈ $69.00K
ILA-9.93 Million
≈ $-26.63K
-0.386x -25.94%
2005-12-31 ILA36.25 Million
≈ $97.18K
ILA-11.11 Million
≈ $-29.78K
-0.306x -24.48%
2004-12-31 ILA49.57 Million
≈ $132.88K
ILA-12.20 Million
≈ $-32.71K
-0.246x -164.19%
2003-12-31 ILA59.81 Million
≈ $160.34K
ILA-5.57 Million
≈ $-14.94K
-0.093x +29.28%
2002-12-31 ILA68.88 Million
≈ $184.67K
ILA-9.08 Million
≈ $-24.33K
-0.132x -11.08%
2001-12-31 ILA80.06 Million
≈ $214.64K
ILA-9.50 Million
≈ $-25.46K
-0.119x -78.69%
2000-12-31 ILA92.51 Million
≈ $248.02K
ILA-6.14 Million
≈ $-16.46K
-0.066x +85.27%
1999-12-31 ILA12.79 Million
≈ $34.28K
ILA-5.76 Million
≈ $-15.45K
-0.451x --

About Compugen

TA:CGEN Israel Biotechnology
Market Cap
$186.23 Million
ILA69.46 Billion ILA
Market Cap Rank
#16898 Global
#202 in Israel
Share Price
ILA734.40
Change (1 day)
-3.41%
52-Week Range
ILA441.40 - ILA924.00
All Time High
ILA6613.00
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more